RecruitingPhase 2NCT06022159

A Study to Evaluate Pre-operative HYPOfractionated Radiation Therapy in Aged (≥ 70 Years Old) or "Fragile" (≥ 65 Years) Patients With Limb or Trunk Soft Tissue SARComa.

Phase II Study Evaluating Pre-operative HYPOfractionated Radiation Therapy in Aged (≥ 70 Years) or "Fragile" (≥ 65 Years) Patients With Limb or Trunk Soft Tissue SARComa.


Sponsor

Institut Claudius Regaud

Enrollment

48 participants

Start Date

Nov 28, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

This is a phase II, multicenter, non-randomized study. The main objective is to evaluate the treatment with hypofractionated radiation therapy in neo-adjuvant situations on wound healing in a population of aged patients (≥ 70 years old) or ≥ 65 years of age defined as "fragile" and treated for soft tissue sarcoma. A maximum of 48 evaluable patients will be included in this study. The patients will receive an hypofractionated radiation therapy prior to conservative surgery. Each patient will be followed for up to 3 years after the end of complete treatment (radiotherapy + surgery).


Eligibility

Min Age: 65 Years

Inclusion Criteria5

  • Patient with histologically confirmed soft tissue sarcoma of the limbs or trunk.
  • Indication for neo-adjuvant or adjuvant radiotherapy.
  • Patient aged ≥ 70 years with a performance status ECOG ≤ 2 and/or aged 65 to 70 years with an ECOG of 2 and identified by the investigator as "fragile".
  • Patient affiliated to a Social Health Insurance in France.
  • Patient able to participate and willing to give informed consent prior performance of any study-related procedures.

Exclusion Criteria10

  • Retroperitoneal, ORL and visceral sarcomas.
  • Previous radiotherapy in the area.
  • Metastatic disease.
  • Concomitant or sequential chemotherapy.
  • Patient requiring total surgery (amputation).
  • Other cancer under treatment.
  • Any condition or pathology contraindicating MRI.
  • Any psychological, familial, geographic or social situation, potentially preventing the provision of informed consent or compliance to study procedure.
  • Patients included in another therapeutic interventional trial.
  • Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

RADIATIONHypofractionated Radiation Therapy

The Hypofractionated Intensity-Modulated Radiation Therapy will be delivered in 5 fractions of 6 Gy each on the Planning Target Volume (PTV). The total dose of 30 Gy will be administered in approximately 1 week.

PROCEDUREConservative treatment

A wide en bloc resection is required (amputation is excluded) while ensuring the best functional preservation. The surgical procedure will take place about 1,5 to 2 months after the end of the radiation therapy.


Locations(11)

Institut Bergonie

Bordeaux, France

Centre Oscar Lambret

Lille, France

Chu de Limoges

Limoges, France

Centre Leon Berard

Lyon, France

Institut Regional Du Cancer de Montpellier

Montpellier, France

Institut Curie

Paris, France

Chu de Poitiers

Poitiers, France

Institut de Cancerologie de L'Ouest

Saint-Herblain, France

Chu de Toulouse

Toulouse, France

IUCT-O

Toulouse, France

Institut Gustave Roussy

Villejuif, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06022159


Related Trials